Amgen’s star PhIII osteoporosis drug romo slammed by surprising cardio risk, a big plus for rival Radius drug
Amgen’s romosozumab, one of its top late-stage drug prospects aimed at osteoporosis, is in some serious trouble.
Late Sunday the big biotech $AMGN and its partner UCB announced what at first glance would appear to be happy news: the late-stage trial comparing romosozumab to Fosamax hit its primary and key secondary endpoints. But as you wind through the release, some big issues start to rise up that raise serious questions about its future — if it has one. And that could make a big difference for its newly approved rival at Radius Health $RDUS.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters